Apimeds Pharmaceuticals US
APUS
8 hedge funds and large institutions have $712K invested in Apimeds Pharmaceuticals US in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
45% more capital invested
Capital invested by funds: $490K → $712K (+$222K)
33% more funds holding
Funds holding: 6 → 8 (+2)
0.08% more ownership
Funds ownership: 0.24% → 0.32% (+0.08%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HTHT
Hemenway Trust Hemenway Trust
Salem,
New Hampshire
|
+$463K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$109K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$57K |
| 4 |
Renaissance Technologies
New York
|
+$51.7K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$440K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.5K |
| 3 |
Goldman Sachs
New York
|
-$21.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.55K |
APUS Hedge Fund Activity: Q3 2025 in Review
8 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Apimeds Pharmaceuticals US (APUS) for Q3 2025, worth a combined $712K — up 45% from $490K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new APUS positions and 4 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hemenway Trust Hemenway Trust, opening a new position worth an estimated $463K. The largest seller was Yorkville Advisors Global, exiting entirely with an estimated $440K sold.
- 8 institutional investors held Apimeds Pharmaceuticals US (APUS) as of Q3 2025, up from 6 in Q2 2025.
- Funds reported $712K of Apimeds Pharmaceuticals US stock for Q3 2025, up 45% quarter-over-quarter.
- 6 funds opened new Apimeds Pharmaceuticals US positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest Apimeds Pharmaceuticals US buyer in Q3 2025 was Hemenway Trust Hemenway Trust, an estimated $463K added.
- The largest Apimeds Pharmaceuticals US seller in Q3 2025 was Yorkville Advisors Global, an estimated $440K sold.
Based on aggregated 13F filings for Q3 2025.